Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 [Yahoo! Finance]
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration [Yahoo! Finance]
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.